PTIX

1.49

7.23% +0.1005

Pre-mercato: 1.36 -0.13 -8.72%

Protagenic Therapeutics Inc (PTIX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.3895

Aprire:

$1.3

Volume 24 ore:

1,413

Capitalizzazione di mercato:

$6.61M

Reddito:

Utile/perdita netta:

$-5.00M

Rapporto P/E:

-1.8861

EPS:

-0.79

Flusso di cassa netto:

$-3.85M

1 W Prestazione:

+15.50%

1M Prestazione:

+10.37%

6M Prestazione:

+83.95%

1 anno Prestazione:

-24.37%

Intervallo 1D:

$1.30

$1.49

Portata 52W:

$0.6797

$2.32

Protagenic Therapeutics Inc Stock (PTIX) Company Profile

Nome

Protagenic Therapeutics Inc

Settore

Healthcare (1211)

Industria

Biotechnology (697)

Telefono

212 994 8200

Indirizzo

149 Fifth Avenue, Suite 500, New York

Dipendente

Cinguettio

Prossima data di guadagno

2024-05-15

Ultimi documenti SEC

PTIX's Discussions on Twitter

Protagenic Therapeutics Inc Borsa (PTIX) Ultime notizie

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - Yahoo Canada Finance

Yahoo Canada Finance

Likelihood of Approval and Phase Transition Success Rate Model - PT-00114 in Treatment Resistant Depression - GlobalData

GlobalData

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

“We owe it to our ancestors and future generations to regroup and rebuild”, Dr. Garo Armen - CIVILNET - CivilNet English

CivilNet English

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 - Yahoo Finance

Yahoo Finance

Meta-analysis Finds Antidepressants Ineffective for Children and Adolescents - Mad in America

Mad in America

Protagenic Therapeutics Inc Azioni (PTIX) Dati Finanziari